|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Implementation of regional Acute Stroke Care Map increases thrombolysis rates for acute ischaemic stroke in Chinese urban area in only 3 months显示文摘Background The rate of intravenous thrombolysis for acute ischaemic stroke remains low in China.We investigated whether the implementation of a citywide Acute Stroke Care Map(ASCaM)is associated with an improvement of acute stroke care quality in a Chinese urban area.Methods The ASCaM comprises 10 improvement strategies and has been implemented through a network consisting of 20 tertiary hospitals.We identified 7827 patients with ischaemic stroke admitted from April to October 2017,and 506 patients underwent thrombolysis were finally included for analysis.Results Compared with‘pre-ASCaM period’,we observed an increased rate of administration of tissue plasminogen activator within 4.5 hours(65.4% vs 54.5%;adjusted OR,1.724;95% CI 1.21 to 2.45;p=0.003)during‘ASCaM period’.In multivariate analysis models,‘ASCaM period’was associated with a significant reduction in onset-to door time(114.1±55.7 vs 135.7±58.4 min,p=0.0002)and onset-to needle time(ONT)(169.2±58.1 vs 195.6±59.3 min,p<0.0001).Yet no change was found in door-to needle time.Clinical outcomes such as symptomatic intracranial haemorrhage,favourable functional outcome(modified Rankin Scale≤2)and in-hospital mortality remained unchanged.Conclusion The implementation of ASCaM was significantly associated with increased rates of intravenous thrombolysis and shorter ONT.The ASCaM may,in proof-of principle,serve as a model to reduce treatment delay and increase thrombolysis rates in Chinese urban areas and possibly other highly populated Asian regions. | Yi Sui Jianfeng Luo Chunyao Dong Liqiang Zheng Weijin Zhao Yao Zhang Ying Xian Huaguang Zheng Bernard Yan Mark Parsons Li Ren Ying Xiao Haoyue Zhu Lijie Ren Qi Fang Yi Yang Weidong Liu Bing Xu | 2021 | Stroke & Vascular Neurology2021，6，1： | 4 |
| 2 | Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial显示文摘 | Craig S Anderson Yining Huang Ji Guang Wang Hisatomi Arima Bruce Neal Bin Peng Emma Heeley Christian Skulina Mark W Parsons Jong Sung Kim Qing Ling Tao Yue Chun Li Jian Dong Jiang Li Wen Tai Jin Li Zhang En Xu Yan Cheng Stephane Heritier Lewis B Morgenste | 2008 | Lancet Neurology2008，，5： | 4 |
| 3 | Effects of Early Intensive Blood Pressure-Lowering Treatment on the Growth of Hematoma and Perihematomal Edema in Acute Intracerebral Hemorrhage: The Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT)显示文摘 | Craig S. Anderson Yining Huang Hisatomi Arima Emma Heeley Christian Skulina Mark W. Parsons Bin Peng Qiang Li Steve Su Qing Ling Tao Yue Chun Li Jian Dong Jiang Li Wen Tai Jin Li Zhang En Xu Yan Cheng Lewis B. Morgenstern John Chalmers Ji Guang Wang | 2010 | Stroke2010，，2： | 3 |
| 4 | Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-Ⅱ (TRACE Ⅱ): rationale and design显示文摘Background and purpose Tenecteplase(TNK)is a promising agent for treatment of acute ischaemic stroke(AIS).We hypothesised that recombinant human TNK tissue-type plasminogen activator(rhTNK-tPA)is non-inferior to rt-PA in achieving excellent functional outcome at 90 days,when administered within 4.5 hours of ischaemic stroke onset.Methods and design Tenecteplase Reperfusion therapy in Acute ischemic Cerebrovascular Events(TRACE)is a phase Ⅲ,multicentre,prospective,randomised,open-label,blinded-end point non-inferiority study.Patients eligible for intravenous thrombolysis therapy are randomised to rhTNK-tPA 0.25 mg/kg(single bolus)to a maximum of 25 mg or rt-PA 0.9 mg/kg(10%bolus+90%infusion/1 hour)to a maximum of 90 mg.Medications considered necessary for the patient’s health may be given at the discretion of the investigator during 90-day follow-up.Study outcomes The primary study outcome is excellent functional outcome defined as modified Rankin Scale(mRS)0–1 at 90 days.Secondary efficacy outcomes include favourable functional outcome defined as mRS≤2 at 90 days,ordinal distribution of mRS and major neurological improvement on the National Institutes of Health Stroke Scale.Safety outcomes are symptomatic intracranial haemorrhage within 36 hours and death from any cause.Discussion There is no completed registration study of TNK in AIS worldwide.TRACE Ⅱ strives to provide evidence for a new drug application for rhTNK-tPA in AIS within 4.5 hours through a well-designed and rigorously executed randomised trial in China. | Shuya Li Bruce C V Campbell Lee H Schwamm Marc Fisher Mark Parsons Hao Li Yuesong Pan Yongjun Wang | 2022 | Stroke & Vascular Neurology2022，7，1： | 2 |
| 5 | Arterial Spin Labeling Identifies Tissue Salvage and Good Clinical Recovery After Acute Ischemic Stroke显示文摘 | Andrew Bivard Peter Stanwell Christopher Levi Mark Parsons | 2013 | Journal of Neuroimaging2013，，3： | 2 |
| 6 | Primary periosteal lymphoma: an unusual presentation of non-Hodgkin’s lymphoma with radiographic, MR imaging, and pathologic correlation显示文摘 | Scot E. Campbell Timothy W. Filzen Shane M. Bezzant Douglas P. Beall Mark P. Burton Timothy G. Sanders Theodore W. Parsons | 2003 | Skeletal Radiology2003，，4： | 1 |
| 7 | Significance of Acute Multiple Brain Infarction on Diffusion-Weighted Imaging显示文摘 | David G. Darby Mark W. Parsons P. Alan Barber Stephen M. Davis | 2000 | Stroke: Journal of the American Heart Association2000，，9： | 1 |
| 8 | Persistent poststroke hypergly- cemia is independently associated with infarct expansion and worse clinical outcome 显示文摘 | Tracey A Mark Baird Parsons W | 2003 | Stroke2003，34，： | 1 |
| 9 | Implementation and outcome of thrombolysis with alteplase 3–4·5 h after an acute stroke: an updated analysis from SITS-ISTR显示文摘 | Niaz Ahmed Nils Wahlgren Martin Grond Michael Hennerici Kennedy R Lees Robert Mikulik Mark Parsons Risto O Roine Danilo Toni Peter Ringleb | 2010 | Lancet Neurology2010，，9： | 1 |
| 10 | Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial显示文摘 | Stephen M Davis Geoffrey A Donnan Mark W Parsons Christopher Levi Kenneth S Butcher Andre Peeters P Alan Barber Christopher Bladin Deidre A De Silva Graham Byrnes Jonathan B Chalk John N Fink Thomas E Kimber David Schultz Peter J Hand Judith Frayne Graeme | 2008 | Lancet Neurology2008，，4： | 1 |
| 11 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 12 | CoInjection Molding of PVC With Other Thermoplastics:Processing,Properties and Applications显示文摘 | Mark Parsons Paul Toyoda | 2002 | Journal of Vinyl & Additive Technology2002，8，3： | 1 |
| 13 | Persistent poststroke hyperglycemia is independentlyassociated with infarct expansion and worse clinical outcome显示文摘 | Tracey A Baird Mark W Parsons Thanh Phan | 2003 | Stroke2003，34，9： | 1 |
| 14 | Steroids in Biliary Atresia: single surgeon, single centre, prospective study显示文摘 | Mark Davenport Chris Parsons Sarah Tizzard Nedim Hadzic | 2013 | Journal of Hepatology2013，，： | 1 |
| 15 | Implementation and outcome of thrombolysis with alteplase 3–4·5 h after an acute stroke: an updated analysis from SITS-ISTR显示文摘 | Niaz Ahmed Nils Wahlgren Martin Grond Michael Hennerici Kennedy R Lees Robert Mikulik Mark Parsons Risto O Roine Danilo Toni Peter Ringleb | 2010 | Lancet Neurology2010，，9： | 1 |
| 16 | Co-injection molding of PVC with other thermoplastics:Processing,properties and applications显示文摘 | Mark Parsons Paul Toyoda | 2002 | Journal of Vinyl & Additive Technology2002，8，3： | 1 |
| 17 | Hematoma growth and outcomes in intracerebral hemorrhage: The INTERACT1 study显示文摘 | Candice Delcourt Yining Huang Hisatomi Arima John Chalmers Stephen M. Davis Emma L. Heeley Jiguang Wang Mark W. Parsons Guorong Liu Craig S. Anderson | 2012 | Neurology2012，，： | 1 |
| 18 | Co-injection molding of pvc with other thermoplastics : Processing, properties and applications 显示文摘 | Mark Parsons Paul Toyoda | 2002 | Journal of Vinyl & Additive Technology2002，8，3： | 1 |
| 19 | Inventory Management Using Constraint Satisfaction and Knowl- edge Refinement Techniques 显示文摘 | Mark Winter D Sleeman Tim Parsons | 1998 | Knowledge-based Systems1998，11，56： | 1 |
| 20 | Co-injection molding of PVC with other thermoplastics : Processing, properties and applications 显示文摘 | Mark Parsons Paul Toyoda | 2002 | Journal of Vinyl & Additive Technology2002，8，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员